Answers are grounded in this paper and cite their sources.
Ulcerative colitis (UC) is a chronic and recurrent inflammatory bowel disease. Current therapeutic strategies achieve clinical remission in only 30%–60% of patients, indicating the crucial need for safer and more effective treatment options. Mitochondrial dysfunction, oxidative stress, and immune dysregulation are critically involved in UC pathogenesis. The NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome, a key regulator of innate immunity, disrupts immune homeostasis disruption when aberrantly activated. In this study, we identified a berberine (BBR) derivative B4, which demonstrated markedly superior efficacy over the parent compound BBR in ameliorating dextran sulfate sodium (DSS)-induced UC mouse model, along with a favorable safety profile. Mechanistic studies revealed that B4 exerts its effects through dual targeting. B4 directly binds to heat shock protein 60 (HSP60), effectively reversing mitochondrial redox and metabolic imbalance, reducing reactive oxygen species (ROS) burst and HSP60 translocation, thereby suppressing NLRP3 activation at the source on one hand. Furthermore, B4 directly targets the NLRP3 protein to inhibit inflammasome assembly, which significantly reducing the secretion of interleukin-1beta (IL-1β) and interleukin-18 (IL-18), and suppressing pyroptosis. This dual-targeting synergy effectively interrupts the vicious positive feedback loop of “mitochondrial dysfunction-NLRP3 inflammasome activation-exacerbated inflammation-aggravated mitochondrial damage,” indicating that B4 is a promising therapeutic agent for UC. Moreover, this novel strategy of co-targeting the “mitochondria-NLRP3 inflammasome axis” provides a new direction for UC drug development.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: